Drug intelligence / Profile preview

Tiankui Congying Granules

Development stage: Unknown
Lead developer: Monyan Pharmaceutical
Administration: Oral

Overview

Tiankui Congying Granules (天癸苁盈颗粒) is an innovative Traditional Chinese Medicine (TCM) candidate classified as a Class 1.1 drug, currently under development by Monyan Pharmaceutical. The drug is formulated as an oral granule specifically for the treatment of menopausal syndrome (perimenopausal syndrome). In TCM theory, "Tiankui" refers to the vital substance responsible for reproductive and developmental functions, which naturally declines during the menopausal transition. This formulation is designed to address the systemic imbalances and symptoms associated with this decline. As a Class 1.1 TCM, it represents a new herbal combination or a significantly modified traditional formula with demonstrated clinical potential. It is currently in Phase 2 clinical trials in China.

Other names: 天癸苁盈颗粒Tiankui Congying Keli

Beyond the preview

Go deeper on Tiankui Congying Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tiankui Congying Granules.